产品说明书

Doxorubicin

Print
Chemical Structure| 23214-92-8 同义名 : Hydroxydaunorubicin
CAS号 : 23214-92-8
货号 : A206785
分子式 : C27H29NO11
纯度 : 98%
分子量 : 543.519
MDL号 : MFCD00869292
存储条件：

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
靶点

  • Topo II
描述 Doxorubicin is a Topoisomerase II (Top2) catalytic inhibitor, also is a broad spectrum antibiotic used in the treatment of cancers, with IC50 of 374 nM for Hela cells.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01891539 - Unknown December 2017 Italy ... 展开 >> Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore Recruiting Pesaro, PU, Italy, 61122 Contact: Giammaria Fiorentini, MD    +390721364124    giammaria.fiorentini@ospedalimarchenord.it    Principal Investigator: Giammaria Fiorentini, MD 收起 <<
NCT00815945 Mesenchymal Tumor ... 展开 >> Carcinosarcoma Leiomyosarcoma 收起 << Phase 2 Completed - Germany ... 展开 >> Charité, Campus Virchow Klinikum, Frauenklinik Berlin, Germany, 13353 Malteser Krankenhaus, Gynäkologie und Geburtshilfe Bonn, Germany, 53123 Klinikum Bremen-Mitte gGmbH, Frauenklinik Bremen, Germany, 28177 Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Dresden, Germany, 01307 Evangelisches Krankenhaus Düsseldorf, Frauenklinik Duesseldorf, Germany, 40217 Universitätsklinikum Essen, Frauenklinik Essen, Germany, 45122 Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe Frankfurt, Germany, 60590 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20251 Gynäkologisch-onkologische Praxis Hannover, Germany, 30177 St. Vincentius Kliniken AG, Frauenklinik Karlsruhe, Germany, 76135 Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie Marburg, Germany, 35043 Klinikum Großhadern, Frauenklinik München, Germany, 81377 Universitätsklinikum Tübingen, Frauenklinik Tübingen, Germany, 72076 Universitätsklinikum Ulm, Universitätsfrauenklinik Ulm, Germany, 89075 Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie Wiesbaden, Germany, 65199 收起 <<
NCT00755261 Sarcoma Soft ... 展开 >>Tissue Sarcoma 收起 << Phase 2 Terminated(The study has been ... 展开 >>terminated due to low accrual.) 收起 << - United States, Maryland ... 展开 >> Johns Hopkins SKCCC Baltimore, Maryland, United States, 21231 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.20mL

1.84mL

0.92mL

18.40mL

3.68mL

1.84mL
参考文献

[1]Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009 May;9(5):338-50.

[2]El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005 Jan 7;5:2.

[3]Wapstra FH, van Goor H, et al. Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. J Pharmacol Toxicol Methods. 1999 Apr-Jun;41(2-3):69-73.

[4]Alshabanah OA, Hafez MM, et al. Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. Oxid Med Cell Longev. 2010 Nov-Dec;3(6):428-33. Epub 2010 Nov 1.

[5]Sun XP, Wan LL, et al. Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart. Arch Pharm Res. 2017 Jul;40(7):875-883.

[6]Chung SW, Kim GC, et al. Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment. Biomaterials. 2018 Nov;182:35-43.